This week, US cannabis giant Tilray Brands announced that it was awarded a tender by Luxembourg’s Ministry of Health to supply the country with medical cannabis flower.
The contract was secured through Tilray Deutschland GmbH, the company’s German subsidiary, further solidifying Tilray’s footprint in the European medical cannabis market.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, called it a ‘testament to the unwavering dedication of our team in providing patients around the world with high-quality medical cannabis products.’
It comes just days after new regulations came into force banning the prescription of high-THC cannabis flower to patients.
As of January 1, 2025, patients will only have access to CBD-rich flower, ‘balanced’ THC/CBD flower, and cannabis oil. Prescriptions for cannabis oil have steadily increased, from 18 bottles in 2022 to 2,850 in 2024, underscoring the program’s expansion in a country of approximately 675,000 people.
A law allowing personal possession of non-medical cannabis and the cultivation of up to four plants per household for personal consumption approved in June 2023 is not impacted by the changes.
Tilray’s involvement in Luxembourg is bolstered by its recent achievements in Germany. In July 2024, the company received Germany’s first cannabis cultivation license under the German Medical Cannabis Act, passed earlier that year.
The license allows Tilray’s Aphria RX GmbH facility to cultivate and manufacture medical cannabis in Germany. Aphria RX’s first commercial-grown cannabis flowers were launched in November 2024.
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
